These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16613761)

  • 1. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
    J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.
    Cummings CJ; Martin TR; Frevert CW; Quan JM; Wong VA; Mongovin SM; Hagen TR; Steinberg KP; Goodman RB
    J Immunol; 1999 Feb; 162(4):2341-6. PubMed ID: 9973513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
    Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2.
    Lippert U; Zachmann K; Henz BM; Neumann C
    Exp Dermatol; 2004 Aug; 13(8):520-5. PubMed ID: 15265017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modes of regulation of cxc chemokine-induced internalization and recycling of human CXCR1 and CXCR2.
    Feniger-Barish R; Ran M; Zaslaver A; Ben-Baruch A
    Cytokine; 1999 Dec; 11(12):996-1009. PubMed ID: 10623425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
    Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
    Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of chemokine receptors CXCR1 and CXCR2 during cardiopulmonary bypass.
    Chishti AD; Dark JH; Kesteven P; Powell H; Snowden C; Shenton BK; Kirby JA; Baudouin SV
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1162-6. PubMed ID: 11726891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.
    Sousa LF; Coelho FM; Rodrigues DH; Campos AC; Barcelos Lda S; Teixeira MM; Rachid MA; Teixeira AL
    Clinics (Sao Paulo); 2013; 68(3):391-4. PubMed ID: 23644861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner.
    Cohen-Hillel E; Yron I; Meshel T; Soria G; Attal H; Ben-Baruch A
    Cytokine; 2006 Jan; 33(1):1-16. PubMed ID: 16406804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
    Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
    J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
    Barsante MM; Cunha TM; Allegretti M; Cattani F; Policani F; Bizzarri C; Tafuri WL; Poole S; Cunha FQ; Bertini R; Teixeira MM
    Br J Pharmacol; 2008 Mar; 153(5):992-1002. PubMed ID: 17891165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells.
    Rittner HL; Labuz D; Schaefer M; Mousa SA; Schulz S; Schäfer M; Stein C; Brack A
    FASEB J; 2006 Dec; 20(14):2627-9. PubMed ID: 17060402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
    Casilli F; Bianchini A; Gloaguen I; Biordi L; Alesse E; Festuccia C; Cavalieri B; Strippoli R; Cervellera MN; Di Bitondo R; Ferretti E; Mainiero F; Bizzarri C; Colotta F; Bertini R
    Biochem Pharmacol; 2005 Feb; 69(3):385-94. PubMed ID: 15652230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of a new interleukin-8 receptor in bovine species.
    Lahouassa H; Rainard P; Caraty A; Riollet C
    Mol Immunol; 2008 Feb; 45(4):1153-64. PubMed ID: 17727952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus.
    Hsieh SC; Wu TH; Tsai CY; Li KJ; Lu MC; Wu CH; Yu CL
    Rheumatology (Oxford); 2008 Feb; 47(2):150-7. PubMed ID: 18208820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.